Pharvaris N.V. (PHVS) Stock Price, Quote & News

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 tria...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 712036410

Website: pharvaris.com

Address:

Grafenauweg 8, Zug, Switzerland

notreload_ai Oct. 8 at 8:28 PM

BofA upgrades $PHVS to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data. https://notreload.xyz/bofa-upgrades-pharvaris/

0 · Reply

NVDAMillionaire Oct. 3 at 7:16 AM

$PHVS Outstanding article that hits the mark on PHVS's current state. So if you want to refresh your PHVS insights or learn about PHVS from scratch, this is a must read. https://beyondspx.com/quote/PHVS/analysis/pharvaris-oral-innovation-set-to-reshape-the-angioedema-market-phvs

0 · Reply

Doozio Sep. 22 at 11:42 PM

$PHVS faatch 💣 or 🐒🍌🧠⏰♾️ on da 🌙

0 · Reply

JarvisFlow Aug. 13 at 2:21 PM

JMP Securities has updated their rating for Pharvaris ( $PHVS ) to Market Outperform with a price target of 52.

0 · Reply

OpenOutcrier Jul. 23 at 12:41 PM

$PHVS (-9.1% pre) Pharvaris Secures Massive $175M Public Offering to Advance Oral HAE Treatment Pipeline https://ooc.bz/l/70946

0 · Reply

DonCorleone77 Jul. 23 at 10:36 AM

$PHVS Pharvaris 8.25M share Spot Secondary priced at $20.00

0 · Reply

DonCorleone77 Jul. 22 at 8:08 PM

$PHVS Pharvaris announces $150M ordinary shares offering

0 · Reply

BioTechHealthX Jul. 19 at 3:38 AM

$PHVS Pharvaris NV is targeting a massive untapped opportunity with its oral HAE therapy. Here’s why early investors are buying in. https://biotechhealthx.com/biotech-news/pharvaris-phvs-the-300m-biotech-that-could-be-the-next-big-thing-in-pharma/

0 · Reply

StockScanners Jul. 15 at 2:49 AM

$PHVS Reached 26.33

0 · Reply

ChazzyTrades Jul. 14 at 7:02 PM

$PHVS buy the dip. Thank me later

0 · Reply

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 1:04 AM EDT - 4 weeks ago

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 5:25 AM EDT - 5 weeks ago

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 12, 2025, 4:05 PM EDT - 2 months ago

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 3:15 PM EDT - 2 months ago

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations

Jul 22, 2025, 9:22 PM EDT - 2 months ago

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Jul 22, 2025, 4:05 PM EDT - 2 months ago

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Jul 18, 2025, 4:41 AM EDT - 2 months ago

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Jul 10, 2025, 6:50 AM EDT - 3 months ago

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Jun 27, 2025, 6:50 AM EDT - 3 months ago

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Jun 16, 2025, 6:50 AM EDT - 4 months ago

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Jun 10, 2025, 6:50 AM EDT - 4 months ago

Pharvaris Announces Annual Meeting of Shareholders

Jun 2, 2025, 6:50 AM EDT - 4 months ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

May 19, 2025, 6:50 AM EDT - 5 months ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

May 13, 2025, 4:05 PM EDT - 5 months ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 6:50 AM EDT - 5 months ago

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Apr 7, 2025, 6:58 AM EDT - 6 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 1, 2025, 6:50 AM EDT - 6 months ago

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Mar 3, 2025, 6:50 AM EST - 7 months ago

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Mar 3, 2025, 6:48 AM EST - 7 months ago

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Jan 13, 2025, 6:50 AM EST - 9 months ago

Pharvaris Outlines 2025 Strategic Priorities

Nov 13, 2024, 4:10 PM EST - 11 months ago

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 12, 2024, 6:50 AM EST - 11 months ago

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Oct 16, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Oct 15, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Host Virtual Investor Event on October 23, 2024

Oct 3, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Sep 5, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Sep 5, 2024, 6:49 AM EDT - 1 year ago

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Sep 5, 2024, 6:48 AM EDT - 1 year ago

Pharvaris Presents Data at the Bradykinin Symposium 2024

Aug 28, 2024, 6:50 AM EDT - 1 year ago

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

May 13, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 8, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 10, 2024, 4:08 PM EDT - 1 year ago

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Apr 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Mar 18, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Mar 6, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Mar 5, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Feb 22, 2024, 6:50 AM EST - 1 year ago

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Feb 16, 2024, 6:50 AM EST - 1 year ago

Pharvaris Announces Extraordinary Meeting of Shareholders

Jan 26, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Present at the WSAAI Annual Meeting 2024

Jan 22, 2024, 6:50 AM EST - 1 year ago

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Jan 5, 2024, 6:50 AM EST - 1 year ago

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Dec 8, 2023, 6:00 PM EST - 1 year ago

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Dec 6, 2023, 8:12 AM EST - 2 years ago

Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Dec 6, 2023, 7:02 AM EST - 2 years ago

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

Dec 6, 2023, 6:50 AM EST - 2 years ago

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Nov 30, 2023, 6:50 AM EST - 2 years ago

Pharvaris to Present at the GA²LEN UCARE Conference 2023

notreload_ai Oct. 8 at 8:28 PM

BofA upgrades $PHVS to Neutral ($27 target). Unique oral drug for angioedema treatment, but current price assumes success of upcoming data. https://notreload.xyz/bofa-upgrades-pharvaris/

0 · Reply

NVDAMillionaire Oct. 3 at 7:16 AM

0 · Reply

Doozio Sep. 22 at 11:42 PM

$PHVS faatch 💣 or 🐒🍌🧠⏰♾️ on da 🌙

0 · Reply

JarvisFlow Aug. 13 at 2:21 PM

JMP Securities has updated their rating for Pharvaris ( $PHVS ) to Market Outperform with a price target of 52.

0 · Reply

OpenOutcrier Jul. 23 at 12:41 PM

$PHVS (-9.1% pre) Pharvaris Secures Massive $175M Public Offering to Advance Oral HAE Treatment Pipeline https://ooc.bz/l/70946

0 · Reply

DonCorleone77 Jul. 23 at 10:36 AM

$PHVS Pharvaris 8.25M share Spot Secondary priced at $20.00

0 · Reply

DonCorleone77 Jul. 22 at 8:08 PM

$PHVS Pharvaris announces $150M ordinary shares offering

0 · Reply

BioTechHealthX Jul. 19 at 3:38 AM

0 · Reply

StockScanners Jul. 15 at 2:49 AM

$PHVS Reached 26.33

0 · Reply

ChazzyTrades Jul. 14 at 7:02 PM

$PHVS buy the dip. Thank me later

0 · Reply

ChazzyTrades Jul. 14 at 12:57 AM

$PHVS ez money

0 · Reply

StockScanners Jul. 11 at 10:57 PM

$PHVS Keep watch if this holds above 23

0 · Reply

GamBino_MaF187 Jul. 11 at 8:06 PM

$PHVS damm...i was watching this today and didnt get in. I thought the data read out was being delayed ???

0 · Reply

BigSqueezeComing Jul. 10 at 11:15 AM

$PHVS Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 By Pharvaris N.V. | July 10, 2025, 6:50 AM

0 · Reply

JarvisFlow Jul. 7 at 11:30 AM

Wedbush has updated their rating for Pharvaris ( $PHVS ) to Outperform with a price target of 27.

0 · Reply

topstockalerts Jul. 4 at 5:43 PM

$PHVS what’s your target for next week? 🍾....🏦....🍾

0 · Reply

Doozio Jul. 4 at 5:15 PM

$PHVS nope it started out of 🐑⏰♾️ during 🐒🍌🧠⏰♾️. Roger about to rock to da $$$$?

0 · Reply

TacticalGeese Jun. 28 at 5:03 PM

$PHVS

0 · Reply

BigSqueezeComing Jun. 27 at 12:51 PM

$PHVS Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit By Pharvaris N.V. | June 27, 2025, 6:50 AM

0 · Reply

Love_To_Learn Jun. 27 at 10:45 AM

$SOUN using old $PHVS 9.93 9.96 9.97 old Porsche models years ago and where they r now meshing the gaps 10.29/10.31 is also me for good reason this is old $NVCN pop rs pop from 2.19/2.21

0 · Reply

G101SPM Jun. 11 at 6:28 PM

#SHOWTIME European Academy of Allergy and Clinical Immunology Congress (June 12-15) Scheduled to appear: $JSPR, $PHVS, $UPB

0 · Reply

BiotechBonesaw Jun. 9 at 2:03 PM

$KALV - Kalvista is still a buy ahead of their PDUFA $PHVS - Pharvaris is a hold well ahead of their HAE activity in 2026 $PHAR - I would sell or avoid this. Pharming will likely lose market shares or valuation with Kalvista’s expected approval & continued rise

1 · Reply

Market Cap	1.20B
Revenue (ttm)	0.00
Net Income (ttm)	-145.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	106,300
Avg Vol	163,926
Day's Range	N/A - N/A
Shares Out	52.29M
Stochastic %K	22%
Beta	-2.77
Analysts	Strong Sell
Price Target	$34.11